REAL SCIENCE. REAL POSSIBILITIES.TB-500 attracts interest around recovery, wound healing and the repair of tendons, ligaments and other soft tissues, although research remains largely preclinical.
Interest centres on regenerative biology: cell migration, vessel formation, wound repair and connective-tissue recovery. Much of the positive signal comes from thymosin β4 or its actin-binding motif rather than direct clinical testing of TB-500.
These cards show what TB-500 is best known for and where the interest comes from. When you want the detail, open Research for the studies or Evidence for a quick view of how strong the support is.
The main reasons this compound attracts attention. The Research and Evidence sections give you the deeper scientific picture.
Repair biology is the main reason TB-500 attracts attention, particularly where tissue recovery is slow or incomplete.
Thymosin β4 and its active-site sequences have shown effects on wound repair, cell migration and regenerative pathways in experimental models. Direct TB-500 evidence is much thinner.
TB-500 is widely discussed around tendon, ligament and soft-tissue recovery, making connective tissue one of its strongest areas of community interest.
The biological rationale comes mainly from thymosin-β4 repair biology and actin-dependent cell movement rather than controlled human TB-500 injury trials.
The short LKKTETQ sequence is especially interesting because it sits within the actin-binding region of thymosin β4.
Experimental research has linked this motif with actin-related biology, endothelial migration and other cellular processes involved in repair.
Formation of new microvessels is an important part of tissue repair and is one of the more compelling biological themes around the thymosin-β4 pathway.
A 2003 study found that a short actin-binding sequence containing LKKTETQ promoted endothelial migration, tubule formation and aortic-ring sprouting in experimental assays.
Recovery depends on more than rebuilding tissue; the local inflammatory and cellular environment also shapes the repair process.
Full-length thymosin β4 has been studied for anti-inflammatory and tissue-protective activity. How fully those effects carry across to TB-500 remains unresolved.
The combination of cell-migration, vascular and repair biology gives TB-500 a broad recovery story that continues to drive research and community interest.
Direct studies of TB-500 itself remain limited, but the surrounding thymosin-β4 literature provides several biologically plausible pathways worth investigating further.
TB-500 is the acetylated 17–23 fragment of thymosin β4. Research around this sequence focuses on cell migration, angiogenesis and repair biology, while direct clinical studies of the fragment remain limited.
TB-500 metabolites were characterized after in-vitro and rat exposure.
PubMed · PMID 38382158 ↗A short sequence containing the LKKTETQ actin-binding region showed angiogenic activity in experimental assays.
PubMed · PMID 14500546 ↗The LKKTETQ-containing actin-binding domain was associated with angiogenesis, wound healing and cell migration in experimental work.
PubMed · PMID 20179146 ↗Human wound-healing research has been reported for full-length thymosin β4.
PubMed · PMID 23050815 ↗This score reflects completed human outcome evidence. A registered or recruiting trial does not count until results are reported.
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Recurring themes from peptide and wellness communities, shown alongside what published research currently suggests.
Community interest in TB-500 is concentrated around injury recovery, tendons and ligaments, return to training and pairing it with BPC-157. Those experiences help identify the questions people care about most, while direct human TB-500 research remains limited.
Experiences can reveal recurring goals, perceived changes and practical questions that formal studies may not yet address. They can suggest what deserves investigation, but cannot isolate the effect of one compound from rehabilitation, time or other changes.
Human and preclinical research helps test whether an idea is biologically plausible, whether it appears in people and how confidently the result can be separated from chance, bias or other parts of recovery.
No direct controlled TB-500 efficacy trial identified
Related thymosin-β4 and actin-motif repair biology provides a plausible rationale
A major area of community interest with relevant biological support, but direct TB-500 human evidence is still needed.
Direct TB-500 evidence remains very limited
Cell-migration and wound-repair pathways are supported in related experimental research
The surrounding biology is encouraging enough to justify interest, while the fragment itself remains under-studied.
Not established for TB-500
Full-length thymosin β4 has anti-inflammatory and tissue-protective research
Related parent-peptide findings are interesting, but they should not be treated as proof of the same effect from TB-500.
No controlled combination trial identified
Each component has a different surrounding research rationale
One of the best-known recovery stacks in peptide communities; combination-specific research would be needed to quantify any added effect.
Community reports can surface patterns worth exploring. Controlled human research is what tests whether those patterns are reliable, clinically meaningful and attributable toTB-500, while the available studies show how far that question has already been answered.
Direct human dosing data are not established, so research context and commonly repeated community patterns are shown separately.
Direct TB-500 work is mainly laboratory and animal research. The figures below are therefore presented as anecdotal protocol patterns, not as a clinically validated regimen.
Community protocols more often describe a change of phase — a higher-frequency loading period followed by a lower-frequency maintenance period — rather than gradually increasing the dose week by week. Where a compound does have trial-defined titration, future pages will show the step-up schedule explicitly.
Translate a figure you are reviewing into vial, liquid-volume and syringe calculations without treating the example as a recommendation.
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
BPC-157 + TB-500
TB-500 has a plausible biological rationale, but the direct human safety database is much thinner than the related thymosin-β4 literature.
FDA's current review says it has not identified human exposure data for drug products containing the thymosin β4 fragment known as TB-500.
Peptide aggregation, impurities, formulation and manufacturing quality can influence the behaviour and immunogenicity of an injectable peptide product.
Safety or efficacy findings for full-length thymosin β4 should not automatically be assigned to the shorter acetylated TB-500 fragment.
Thymosin β4 and TB-500 are prohibited in sport under the World Anti-Doping Code growth-factor category.
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
FDA says it has not identified human exposure data for drug products containing the thymosin beta-4 fragment known as TB-500 and has highlighted potential immunogenicity, aggregation and peptide-impurity concerns.
FDA safety review ↗Thymosin beta-4 / TB-500 is prohibited in sport under the World Anti-Doping Code growth-factor category.
Sport Integrity / WADA context ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.